Oxaliplatin: Pharmacokinetics and chronopharmacological aspects

Clinical Pharmacokinetics

Volumn 38, Issue 1, 2000, Pages 1-21

  Lévi, Francis ^a,d   Metzger, Gérard ^a   Massari, Claire ^a,b   Milano, Gérard ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ATOMIC ABSORPTION SPECTROMETRY; CELL MEMBRANE TRANSPORT; CHRONOPHARMACOLOGY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; HUMAN; INFUSION PUMP; KIDNEY FAILURE; LIPOPHILICITY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; META ANALYSIS; MOTOR NEUROPATHY; MUSCLE CRAMP; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

EID: 0033959065     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038010-00001     Document Type: Review

References (115)

1. 1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from platinum electrode. Nature 1965; 205: 698-9
2. 2. Loehrer PJ, Einhorn LA. Cisplatin. Ann Intern Med 1984; 11: 704-13
3. 3. Reed E. Platinum analogs. In: De Vita V, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia (PA): J.B. Lippincott Co., 1993: 390-400
4. 4. Ozols RF, Corden BF, Jacob J, et al. High dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 19-24
5. 5. Hrushesky WJ. Circadian timing of cancer chemotherapy. Science 1985; 228: 73-5
6. 6. Levi F, Benavides M, Chevelle C, et al. Chemotherapy of advanced ovarian cancer with 4′-0-tetrahydropyranyl adriamycin (THP) and cisplatin: a phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol 1990; 8: 705-14
7. 7. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994; 12: 2066-70
8. 8. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10 (5): 706-17
9. 9. Kidani Y, Inagaki K, Tsukagoshi S. Examination of antitumor activity of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gann 1974; 67: 921-2
10. 10. Cleare M, Hydes P, Molerbi B, et al. Antitumor platinum complexes: relationship between chemical properties and activity. Biochimie (Paris) 1978; 60: 835-50
11. 11. Burchenal JH, Irani G, Kern K, et al. 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Rec Res Cancer Res 1980; 74: 146-55
12. 12. Kidani Y, Inagaki K, Iigo M, et al. Antitumor activity of 1,2 diaminocyclohexane-platinum complexes against sarcoma 180 in ascites form. J Med Chem 1978; 21: 1315-18
13. 13. Kidani Y, Noji N, Tashiro T. Antitumor activity of platinum (II) complexes of 1,2 -diamminocyclohexane isomers. Jpn J Cancer Res 1980; 71: 637-43
14. 14. Mathé G, Kidani Y, Noji M, et al. Antitumor activity of 1-OHP in mice. Cancer Lett 1985; 27: 135-43
15. 15. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303
16. 16. Schilder RJ, LaCreta FP, Perez RP, et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 1994; 54: 709-17
17. 17. Redfern PH, Lemmer B, editors. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Vol. 125. Berlin: Springer-Verlag, 1997: 668
18. 18. Bruguerolle B. Chronopharmacokinetics: current status. Clin Pharmacokinet 1998; 35: 83-94
19. 19. Hrushesky WJ, Lévi F, Halberg F, et al. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res 1982; 42: 945-9
20. 20. Lévi F, Hrushesky WJ, Blomquist CH, et al. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 1982; 42: 950-5
21. 21. Boughattas N, Lévi F, Fournier C, et al. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharm Exp Ther 1990; 255: 672-9
22. 22. Hecquet B, Meynadier J, Bonneterre J, et al. Time dependency in plasmatic protein binding of cisplatin. Cancer Treat Rep 1985; 69: 79-83
23. 23. Hrushesky WJ, Borch R, Levi F. Circadian-stage dependent urinary pharmacokinetics of cisplatin. Man Clin Pharmacol Ther 1982; 32: 330-9
24. 24. Boughattas N, Lévi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-I) oxalatoplatinum (II) in mice. Cancer Res 1989; 49: 3362-8
25. 25. Boughattas NA, Hecquet H, Fournier C, et al. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Disp 1994; 15 (864): 1-13
26. 26. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-50
27. 27. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29 (9): 1280-4
28. 28. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900
29. 29. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-70
30. 30. Misset JL, Chollet P, Vennin P, et al. Multicentric phase II-III trial of oxaliplatin (L-OHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer: toxicity efficacy results [abstract 1266]. Proc Am Soc Clin Oncol 1997; 16: 354a
31. 31. Machover D, Diaz-Rubio E, De Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8
32. 32. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients (Digestive Group of French Federation of Cancer Centers). J Clin Oncol 1998; 16: 2739-44
33. 33. De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-19
34. 34. Fournier C, Hecquet B, Bastian G, et al. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin. Cancer Chemother Pharmacol 1992; 29: 461-6
35. 35 Fournier C, Hecquet B. Rapport sur l'interaction entre le I-OHP et les solutions commerciales de fluorouracile et d'acide folinique. Lausanne: Debiopharm, 1992 (data on file)
36. 36. Determination of compatibility of Eloxatin® with Mélodie pump components and infusion bags (RSTDSD-I9980375-EN-EN01). Paris: SANOFI, 1998 (data on file)
37. 37. Luo FR, Yen TY, Wyrick SD, et al. High-performance liquid Chromatographic separation of the biotransformation products of oxaliplatin. J Chromatogr B Biomed Sci Appl 1999; 724: 345-56
38. 38. Luo FR, Wyrick SD, Chaney SG. Biotransformation of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol 1999; 13: 159-63
39. 39. Pinto AL, Lippard SJ. Sequence-dependent termination of in vitro DNA synthesis by cis-and trans-diamminedichloroplatinum (II). Proc Natl Acad Sci USA 1985; 82: 4616-19
40. 40. Butour JL, Mazard AM, Macquet JP. Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem Biophys Res Commun 1985; 133: 347-53
41. 41. Knox RJ, Friedlos F, Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclohutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972-9
42. 42. Saris CP, van de Vaart PJM, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17: 2763-9
43. 43. Woynarowski JM, Chapman WG, Napier C, et al. Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998; 54: 770-7
44. 44. Boudny V, Vrana O, Gaucheron F, et al. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 1992; 20: 267-72
45. 45. Nehme A, Baskaran R, Nebel S, et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 1999; 79: 1104-10
46. 46. Li XM, Metzger G, Filipski E, et al. Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxicity in mice. Toxicol Appl Pharmacol 1997; 143: 281-90
47. 47. Li XM, Metzger G, Filipski E, et al. Modulation of nonprotein sulfhydryl compounds rhythm with buthionine sulfoximine: relationship with oxaliplatin toxicity in mice. Arch Toxicol 1998; 72: 574-9
48. 48. Metzger G, Maffrand JP, Misset JL, et al. Kinetics of platinum (Pt) binding to DNA in mouse organs after oxaliplatin (I-OHP) administration. Effect of buthionine sulfoximine (BSO) [abstract 2597]. Proc Am Assoc Cancer Res 1999; 40: 392
49. 49. Mistry P, Loh SY, Kelland LR, et al. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int J Cancer 1993; 55: 848-56
50. 50. Pendyala L, Creaven PJ, Perez R, et al. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol 1995; 36: 271-8
51. 51. Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43: 237-50
52. 52. Debiopharm SA. Oxaliplatin: investigator's brochure. 4th ed. Lausanne: Debiopharm, 1998 May 11
53. 53. Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin and their biotransformation productsutilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 1999; 44: 29-38
54. 54. Screnci D, Er HM, Hamblay TW, et al. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enentiomers related to ormaplatin and oxaliplatin. Br J Cancer 1997; 76: 502-10
55. 55. Luo FR, Wyrick SD, Chaney SG. Pharmacokinetics and biotransformation of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 1999; 44: 19-28
56. 56. Boughattas N. Effects of anticancer agent oxaliplatin on the excitability properties of the peripheral nervous system [abstract 2583]. Proc Am Assoc Cancer Res 1994; 35: 433
57. 57. Kizu R, Higashi S, Kidani Y, et al. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum (II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 1993; 31: 475-80
58. 58. Pendyala L, Creaven P. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6
59. 59. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65
60. 60. Raymond E, Lawrence R, Izbicka E, et al. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998; 4: 102I-9
61. 61. Fischel JL, Etienne MC, Formento P, et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4: 2529-35
62. 62. Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25: 13-22
63. 63. Garufi C, Pietrangeli A, Brienza S, et al. Electrophysiological evaluation of oxaliplatin neurotoxicity [abstract 938]. Proc Am Soc Clin Oncol 1999; 18: 244a
64. 64. Garufi C, Nistico C, Brienza S, et al. Oxaliplatin (L-OHP) activity in anthracycline (ANT)-resistant metastatic breast cancer (MBC) patients [abstract 595]. Proc Am Soc Clin Oncol 1997; 16: 170a
65. 65. Germann N, Brienza S, Rotarski M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory-recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10: 351-4
66. 66. Levi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst 1994; 86: 1608-17
67. 67. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14 (II): 2950-8
68. 68. Levi F, Zidani R, Misset JL, et al. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6
69. 69. De Gramont A, Figer A, Seymour M, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer (CRC) [abstract 985]. Proc Am Assoc Clin Oncol 1998; 17: 257a
70. 70. Levi F, Zidani R, Brienza S, et al. A mullicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal cancer. Cancer 1999; 85 (12): 2532-40
71. 71. Giacchetti S, Perpoint B, Zidani R, et al. Chronotherapy Phase III multicenter randomized trial of oxaliplatin addition to chronomodulated 5-fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. In press
72. 72. Leroy AR, Wehling ML, Sponseller HL, et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977; 18: 184-90
73. 73. Tothill P, Mathesson LM, Smyth JF, et al. Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry. J Anal Atomic Spectroscopy 1990; 5: 619-22
74. 74. Allain P, Berre S, Mauras Y, et al. Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma. Biol Mass Spectrometry 1992; 21: 141-3
75. 75. Mauldin SK, Gibbons G, Wyrick SD, et al. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 1988; 48, 5136-44
76. 76. Taguchi T, Tsukagoshi S, Furue H, et al. Phase I clinical study of oxaliplatin. Gan To Kagaku Ryoho 1998; 25: 1899-907
77. 77. Gamelin E, Boisdron-Cell M, Le Bouil A, et al. Determination of unbound platinum alter oxaliplatin administration: comparison of currently available methods and influence of various parameters. Anti-Cancer Drugs 1998; 9: 223-8
78. 78. Gamelin E, Le Bouil A, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997; 3: 891-9
79. 79. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. In press
80. 80. Kern W, Braess J, Bottger B, et al. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res 1999; 5: 761-5
81. 81. Graham MA, Gamelin E, Misset JL, et al. Clinical pharmacokinetics of oxaliplatin [abstract 1088]. Proc Am Assoc Cancer Res 1998; 39: 159
82. 82. Graham MA, Lockwood G, Morrison JG, et al. Clinical pharmacokinetics of oxaliplatin [abstract 5]. 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (ISPtC '99); 1999 Mar 28-31; Oxford.
83. 83. Allen J, Graham MA, Firth J, et al. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer [abstract 1086]. Proc Am Assoc Cancer Res 1998; 39: 159
84. 84. Allain P, Brienza S, Gamelin E, et al. Oxaliplatin induced platinum DNA adducts in white blood cells of cancer patients [abstract 2760]. Proc Am Assoc Cancer Res 1996; 37: 404
85. 85. Graham MA, Lockwood GF, Cunningham D, et al. Pharmacokinetics of oxaliplatin in special patient populations [abstract 728]. Proc Am Soc Clin Oncol 1999; 18: 189a
86. 86. Wasserman E, Cuvier C, Lokiec F, et al. Combination of Oxaliplatin plus Irinotecan in patients with gastrointestinal tumors: results of two Phase I studies with pharmacokinetics. J Clin Oncol 1999; 17: 1751-9
87. 87. Gamelin E, Boisdron-Celle M, Allain P, et al. Pharmacokinetic interference between oxaliplatin and fluorouracil: delayed metabolism inhibition by I-OHP [abstract 1500]. Proc Am Assoc Cancer Res 1997; 38: 223
88. 88. Papamichael D, Joel SP, Seymour MT, et al. Pharmacokinetic interaction between 5-fluorouracil and oxaliplatin [abstract 777]. Proc Am Soc Clin Oncol 1998; 17: 202a
89. 89. Petit E, Milano G, Levi F, et al. Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res 1988; 48: 1676-9
90. 90. Harris B, Song R, Soong S, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201
91. 91. Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin Pharm Ther 1994; 56: 190-201
92. 92. Thiberville L, Compagnon C, Moore N, et al. Plasma 5-fluorouracil and alpha-fluoro-beta-alanine accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1994; 35: 64-70
93. 93. Himmelstein KJ, Patton TF, Belt RJ, et al. Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 1981; 29: 658-64
94. 94. Vermorken JB, Van der Vijjgh WJF, Klein I, et al. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 1984; 68: 505-13
95. 95. Vermorken JB, Van der Vijjgh WJF, Klein I, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986; 39: 136-44
96. 96. Elferink F, Van der Vijgh WJF, Klein I, et al. Pharmacokinetics of carboplatin after IV administration. Cancer Treat Rep 1987; 71: 1231-7
97. 97. Van der Vijjgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242-61
98. 98. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 1997; 33: 161-83
99. 99. Gullo JJ, Litterst CL, Maguire PJ, et al. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 1980; 5: 21-6
100. 100. Forastière AA, Belliveau JF, Goren MP, et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res 1988; 48: 3869-74
101. 101. Ikeda K, Terashima M, Kawamura H, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998; 28: 168-75
102. 102. Labrecque G, Bélanger PM, Doré F, et al. 24-hour variations in the distribution of labeled microspheres to the intestine, liver and kidneys. Annu Rev Chronopharmacol 1989; 5: 445-8
103. 103. Cambar J, Pons M. New trends in chronotoxicology. In: Redfern PH, Lemmer B, editors. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Berlin: Springer-Verlag, 1997: 557-88
104. 104. Bruguerolle B, Prat M. Temporal variations of membrane permeability to local anaesthetic agents, bupivacaine and mepivacaine, documented by their erythrocytic passage. Annu Rev Chronopharmacol 1989; 5: 227-30
105. 105. Dermont MC, Lévi F. Circadian system alterations during cancer processes: a review. Int J Cancer 1997; 70: 241-7
106. 106. Lévi F. Therapeutic implications of circadian rhythms in cancer patients. In: Chadwick D, Goode J, editors. Mechanisms and biological significance of pulsatile hormone secretion [Novartis Foundation Symposium 227]. Chichester: J. Wiley & Son, 2000: 119-142
107. 107. Metzger G, Massari C, Renée N, et al. Variations in platinum plasma levels depending on chronomodulated oxaliplatin peak time [abstract 863]. Proc Am Soc Clin Oncol 1997; 16: 244a
108. 108. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991; 325: 986-90
109. 109. Lemmer B, Nold G. Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharm 1991; 32: 627-9
110. 110. Touitou Y, Touitou C, Bogdan A, et al. Differences between young and elderly subjects in seasonal and circadian variations of total plasma proteins and blood volume as reflected by hemoglobin, hematocrit and erythrocyte counts. Clin Chem 1986; 32: 801-4
111. 111. Bruguerolle B, Arnaud C, Lévi F, et al. Physiopathological alterations of alpha-1-acid glyprotein temporal variations: implications for chronopharmacology. Poceeding of the Symposium on Genetics, Biochemistry, PHysiological Functions and Pharmacology of Alpha-1-acid Glyprotein; 1988 Sep 1-2; Lausanne (Switzerland). New York (NY): Liss, 1989: 199-214
112. 112. Lévi F, Benavides M, Touitou Y, et al. Circadian rhythm in the membrane of circulating human blood cells: microviscosity and number of benzodiazepine binding sites. A search for regulation by plasma ions, nucleotides, proteins or hormones. Chronobiol Int 1987; 4: 235-43
113. 113. Haus E. Chronobiology of circulating blood cells and platelets. In: Touitou Y, Haus E, editors. Biologic rhythms in clinical and laboratory medicine. Berlin: Springer Verlag, 1992: 504-26
114. 114. Andreotti F, Patti G. Chapter 19: cancer chemotherapy. Chronobiology of the haemostatic system. In: Redfern PH, Lemmer B, editors. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Berlin: Springer-Verlag, 1997: 533-55
115. 115. Calvert H, Judson I, Van der Vijgh WJ. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv 1993; 17: 189-217